Exploration of Management Model and Intervention Research on Fear of Cancer Recurrence

Cancer Patients Clinical Trial

Official title:

Exploration of Management Model and Intervention Research on Fear of Cancer Recurrence

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05922423
• Other study ID #: NFEC-2023-008
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2024
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Nanfang Hospital, Southern Medical University
• Contact: Luo xian, Doctor
• Phone: 15521073773
• Email: 2443180803[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

1. Through cross-sectional investigation and research, construct an fear of cancer recurrence warning model to identify and screen high fear of cancer recurrencecancer populations, in order to identify predictive factors for high fear of cancer recurrence, study how cancer patients develop susceptibility to fear of cancer recurrence during the diagnosis and treatment process, including which participating factors, explore the development trajectory of fear of cancer recurrence, and effectively prevent the occurrence of high-level fear of cancer recurrence. 2. Through randomized controlled trials, conduct a study on mindfulness and stress reduction psychosocial intervention for high-level fear of cancer recurrence patients, verify the effectiveness of psychosocial intervention measures targeting domestic cancer populations, and improve standardized intervention methods, intervention time, and treatment content.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 130
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged = 18 years old
• Consistent with pathological diagnosis of cancer
• Able to understand and comply with research protocols
• Written informed consent can be provided
• Own and know how to use smart ·terminals (such as smartphones, tablets, computers, etc.)

Exclusion Criteria:

• Patients with mental illness and consciousness disorders;
• Patients with cancer metastasis or recurrence
• End of life treatment for patients.

Related Conditions & MeSH terms

• Cancer Patients
• Recurrence

Intervention

Behavioral:
• MBSR
Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
• health education
For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Nanfang Hospital, Southern Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fear of cancer recurrence	subjects' fear of cancer recurrence indicators at baseline	Baseline
Primary	Fear of cancer recurrence	Change in fear of cancer recurrence score compared to baseline at 8 weeks.	At the end of the 8-week intervention
Primary	Fear of cancer recurrence	Fear of cancer recurrence after one month of intervention	1 mouth
Primary	Fear of cancer recurrence	Fear of cancer recurrence after three months of intervention	3 months